https://bdsc.indiana.edu/stocks/misc/sparc.html

Cross 1

Between the a female integrase line and any split gal4 line.

Female (X25)	(J74) Male
nSyb-PhiC31; S[1]/CyO; Pri[1]/TM6B, Tb[1]	w[1118]/y; AD/AD; DBD/DBD

You want to collect:

F1

nSyb-PhiC31/y; AD/CyO; DBD/TM6B, Tb (Male, NO S[1], NO Pri[1])

Cross 2

Then, cross that with any of the SPARC-Syn-CsChrimson lines (U57-U59).


Male F1	(U58-59) Female
nSyb-PhiC31/y; AD/CyO; DBD/TM6B, Tb	+; SPARC2-D-Syn21-CsChrimson; +

You want to collect:

F1

nSyb-PhiC31/+; AD/SPARC2-D-Syn21-CsChrimson; DBD/+ (Female, NO CyO, NO TM6B,Tb)

These should be allowed to adult until they are about 5-6 d/o, and then put on retinal for a day.



SPARC and SPARC2 user guide

a) Important notes:

- 1. SPARC and SPARC2 activity requires a minimum of three transgenes: 1) SPARC-effector, 2) promoter-PhiC31, and 3) enhancer-GAL4.
- 2. SPARC-effector or SPARC2-effector and promoter-PhiC31 transgenes MUST be maintained in separate stocks. If both transgenes are present in the same fly, there is a possibility that unanticipated PhiC31 expression in the germline will lead to stable recombination of the SPARC or SPARC2 cassette.
- 3. For all new SPARC-effector combinations, we recommend using SPARC2.
- b) Example crossing schemes for SPARC or SPARC2

$$\frac{+}{+}; \begin{array}{l} \textit{SPARC2-Effector}; + \chi & \frac{+}{Y}; \begin{array}{l} \textit{promoter*-PhiC31}; \\ \textit{su(Hw)attP5} \end{array}; \begin{array}{l} \textit{enhancer-Gal4} \\ \textit{attP2} \end{array} \end{array} OR$$

$$\frac{+}{+}; \begin{array}{l} \textit{SPARC2-LexA::p65}; \\ \textit{(near {attP40})} \end{array}; \begin{array}{l} \textit{lexAop-effector} \\ \textit{(variable)} \end{array} \chi \xrightarrow{\frac{+}{Y}}; \begin{array}{l} \textit{promoter*-PhiC31}; \\ \textit{su(Hw)attP5} \end{array}; \begin{array}{l} \textit{enhancer-GAL4} \\ \textit{{attP2}} \end{array}$$

Using split-Gal4 Drivers:

$$\frac{+}{+} ; \frac{SPARC2\text{-effector}}{(near \{attP40\})}; + X = \frac{\{attp18\}}{Y} ; \frac{enhancer\text{-}GAL4AD**}{\{attP40\}}; \frac{enhancer\text{-}GAL4DBD}{\{attP40\}}; OR$$

$$\frac{-}{+} ; \frac{SPARC2\text{-}LexA::p65\text{.}lexAop\text{-}effector}{(near \{attP40\})}; \frac{\{attp18\}}{Y}; \frac{enhancer\text{-}GAL4AD}{Y}; \frac{enhancer\text{-}GAL4DBD}{\{attP2\}}; \frac{enhancer\text{-}GAL4AD}{\{attP40\}}; \frac{enhancer\text{-}GAL4DBD}{\{attP2\}}$$

^{*} Available stocks: 20XUAS-PhiC31, tub-PhiC31, and nSyb-PhiC31

^{*} Available stocks: 20XUAS-PhiC31 and nSyb-PhiC31.

^{**} Note: Janelia split-Gal4 drivers use the p65ADZp activating domain²¹.